Balyasny Asset Management
LCTX icon

Balyasny Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Balyasny Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-56,362
Closed -$84.5K – 2573
2023
Q1 		$84.5K Buy
56,362
+32,622
+137% +$45.5K ﹤0.01% 2334
2022
Q4 		$27.8K Buy
+23,740
New +$29.9K ﹤0.01% 2438
2022
Q3 		– Sell
-10,432
Closed -$16K – 3112
2022
Q2 		$16K Buy
+10,432
New +$13.8K ﹤0.01% 2512
2021
Q2 		– Sell
-36,162
Closed -$85K – 2223
2021
Q1 		$85K Buy
+36,162
New +$86.8K ﹤0.01% 1648
2018
Q2 		– Sell
-34,416
Closed -$81K – 2003
2018
Q1 		$81K Buy
+34,416
New +$80.7K ﹤0.01% 1841
2015
Q4 		– Sell
-12,700
Closed -$31K – 1366
2015
Q3 		$31K Hold
12,700
– – ﹤0.01% 1106
2015
Q2 		$37K Buy
+12,700
New +$49.2K ﹤0.01% 1112

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LCM
Laurion Capital Management New York $1.07B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return